Summary
This study has compared the preferential killing of three multidrug-resistant (MDR) KB cell lines, KB-C1, KB-A1 and KB-V1 by two inhibitors of glucosylceramide synthase, 1-phenyl-2-decanoylamino-3-morpholino-1-propanol (PDMP) and 1-phenyl-2-hexadecanoylamino-3-pyrrolidino-1-propanol (PPPP), to the killing produced by these compounds in the drug-sensitive cell line, KB-3-1. Both of the inhibitors caused much greater induction of apoptosis in each of the three MDR cell lines than in the drug-sensitive cell line, as judged by morphological assay and confirmed by poly-(ADP-ribose)-polymerase cleavage. The highest level of apoptosis was produced following 24-h exposure to 5 μM PPPP. This treatment produced 75.8 (± 7.1)%, 73.6 (± 9.8)% and 75.3 (± 6.4)% apoptotic cells in the three MDR cell lines respectively, compared to 19.0 (± 9.8)% in the drug-sensitive cell line. A reduction in glucosylceramide level following inhibitor treatment occurred in KB-3-1 cells as well as in the MDR cell lines, suggesting that the increased apoptotic response in the MDR cells reflected a different downstream response to changes in the levels of this lipid in these cells compared to that in the drug-sensitive cells. These results suggest that the manipulation of glucosylceramide levels may be a fruitful way of causing the preferential killing of MDR cells in vitro and possibly in vivo.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Abe, A, Radin, NS, Shayman, JA, Wotring, LL, Zipkin, RE, Sivakumar, R, Ruggieri, JM, Carson, KG & Ganem, B (1995). Structural and stereochemical studies of potent inhibitors of glucosylceramide synthase and tumor cell growth. J Lipid Res 36: 611–621.
Bell, SE, Quinn, DM, Kellett, GL & Warr, JR (1998). 2-deoxy-D-glucose preferentially kills multidrug-resistant human KB carcinoma cell lines by apoptosis. Br J Cancer 78: 1464–1470.
Bentley, J, Bell, SE, Quinn, DM, Kellett, GL & Warr, JR (1996). 2-deoxy-D-glucose toxicity and transport in human multidrug-resistant KB carcinoma cell lines. Oncol Res 8: 77–84.
Bentley, J, Quinn, DM, Pitman, RS, Warr, JR & Kellett, GL (1997). The human KB multidrug-resistant cell line KB-C1 is hypersensitive to inhibitors of glycosylation. Cancer Lett 115: 221–227.
Cohen, JS & Lyon, RC (1987). Multinuclear NMR study of the metabolism of drug-sensitive and drug-resistant human breast cancer cells. Ann NY Acad Sci 508: 216–228.
Dobrowsky, RT & Hannun, YA (1992). Ceramide stimulates a cytosolic protein phosphatase. J Biol Chem 267: 5048–5051.
Hannun, YA & Bell, RM (1989). Functions of sphingolipids and sphingolipid breakdown products in cellular regulation. Science 243: 500–507.
Hoffman, K & Dixit, VM (1998). Ceramide in apoptosis – does it really matter?. TIBS 23: 374–377.
Jarvis, WD, Grant, S & Kolesnick, RN (1996). Ceramide and the induction of apoptosis. Clin Cancer Res 2: 1–6.
Kaufmann, SH, Desnoyers, S, Ottaviano, Y, Davidson, NE & Poirier, GG (1993). Specific cleavage of poly-(ADP-ribose)-polymerase: an early marker of chemotherapy-induced apoptosis. Cancer Res 53: 3976–3985.
Laemmli, UK (1970). Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680–685.
Lavie, Y, Cao, H, Bursten, SL, Giuliano, AE & Cabot, MC (1996). Accumulation of glucosylceramides in multidrug-resistant cells. J Biol Chem 271: 19530–19536.
Ling, V (1992). P-glycoprotein and resistance to anti-cancer drugs. Cancer 69: 2603–2609.
Lozano, J, Berra, E, Municio, MM, Diaz-Meco, MF, Dominguez, I, Sanz, L & Moscat, J (1994). Protein kinase C-ζ is critical for NFκB-dependent promoter activation by sphingomyelinase. J Biol Chem 269: 19200–19202.
Luberto, C & Hannun, YA (1998). Sphingomyelin synthase, a potential regulator of intracellular levels of ceramide and diacylglycerol during SV 40 transformation. Does sphingomyelin synthase account for the putative phosphatidylcholine-specific phospholipase C?. J Biol Chem 273: 14550–14559.
Lucci, A, Cho, WI, Han, T, Giuliano, AE, Morton, DL & Cabot, MC (1998). Glucosylceramide: a marker for multiple-drug resistant cancers. Anticancer Res 18: 475–480.
Marsh, NL, Elias, PM & Holleran, WM (1995). Glucosylceramides stimulate murine epidermal hyperproliferation. J Clin Invest 95: 2903–2909.
Martin, SJ, Reutelingsperger, CPM, McGahon, AJ, Rader, JA, van Schie, RCAA, LaFace, DM & Green, DR (1995). Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: inhibition by overexpression of Bcl-2 and Abl. J Exp Med 182: 1545–1556.
Mathias, S, Dressler, KA & Kolesnick, RN (1991). Characterization of a ceramide-activated protein kinase: stimulation by tumor necrosis factor-α. Proc Natl Acad Sci USA 88: 10009–10013.
Radin, NS (1994). Rationales for cancer chemotherapy with PDMP, a specific inhibitor of glucosylceramide synthase. Mol Chem Neuropathol 21: 111–127.
Radin, NS (1996). Treatment of Gaucher disease with an enzyme inhibitor. Glycoconj J 13: 153–157.
Radin, NS, Shayman, JA & Inokuchi, JI (1993). Metabolic effects of inhibiting glucosylceramide synthesis with PDMP and other substances. Adv Lipid Res 26: 183–213.
Rani, CS, Abe, A, Chang, Y, Rosenzweig, N, Saltiel, AR, Radin, NS & Shayman, JA (1995). Cell cycle arrest induced by an inhibitor of glucosylceramide synthase. J Biol Chem 270: 2859–2867.
Volm, M (1998). Multidrug resistance and its reversal. Anticancer Res 18: 2905–2918.
Author information
Authors and Affiliations
Additional information
Correspondence to: JR Warr
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Nicholson, K., Quinn, D., Kellett, G. et al. Preferential killing of multidrug-resistant KB cells by inhibitors of glucosylceramide synthase. Br J Cancer 81, 423–430 (1999). https://doi.org/10.1038/sj.bjc.6690711
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690711
Keywords
This article is cited by
-
LC-MS based sphingolipidomic study on A549 human lung adenocarcinoma cell line and its taxol-resistant strain
BMC Cancer (2018)
-
Targeting glucosylceramide synthase sensitizes imatinib-resistant chronic myeloid leukemia cells via endogenous ceramide accumulation
Journal of Cancer Research and Clinical Oncology (2011)
-
GCS induces multidrug resistance by regulating apoptosis-related genes in K562/AO2 cell line
Cancer Chemotherapy and Pharmacology (2010)
-
Targeting glucosylceramide synthase downregulates expression of the multidrug resistance gene MDR1 and sensitizes breast carcinoma cells to anticancer drugs
Breast Cancer Research and Treatment (2010)
-
Prognostic relevance of glucosylceramide synthase (GCS) expression in breast cancer
Journal of Cancer Research and Clinical Oncology (2009)